Zeria Group’s subsidiary Tillotts Pharma has completed the acquisition of AstraZeneca‘s Entocort (budesonide) global rights outside the US for around $215m.
The deal was announced in the second week of this month.
Entocort is a gastroenterology medicine to treat patients with mild to moderate Crohn’s disease and ulcerative colitis.
As part of the deal, Tillotts has acquired rights to sell and develop Entocort capsules and enema formulations outside the US. The deal will not include the transfer of any AstraZeneca employees or facilities.
In capsule formulation, Entocort is a first-line therapy indicated to induce and maintain clinical remission of mild to moderate active Crohn’s disease involving the ileum and ascending colon.
It is indicated to induce and maintain clinical remission of distal ulcerative colitis in the rectum, sigmoid colon and descending colon in the enema form.
Entocort is currently commercialised in around 40 countries and reported sales of about $53m outside the US in 2014.
The regulatory submission for Entocort is expected in the coming months in Japan.
AstraZeneca has established partnership with Par Pharmaceutical to commercialise Entocort in the US.
Tillotts Pharma is involved in the development of innovative pharmaceutical products, medical devices and diagnostics in the field of gastroenterology.
The firm markets its own products, including Asacol and Colpermin, as well as VistaPrep and in-licensed products such as Simtomax in around 55 countries through its own subsidiaries.
Image: High-magnification micrograph of Crohn’s disease. Biopsy of colon. H&E stain. Photo: courtesy of Nephron.